Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial

NCT06922279 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT06922279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06922279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 30, 2024
Completion date
November 30, 2029
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal cancer (gc)